Opinion|Videos|July 22, 2024
Head-to-head Study of Upadacitnib and Dupilumab in Atopic Dermatitis (Level Up)
Author(s)Christopher G. Bunick, MD, PhD
An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.
Advertisement
Episodes in this series
- Head-to-head studies of systemic treatments and studies evaluating sequencing of systemic treatments are rare. Results of one such study, Level Up, were recently presented at RAD 2024. Can you describe the study briefly and discuss primary and secondary outcomes in phase 3b/4 study that compared upadacitnib and dupilumab (
Level Up , RAD 2024)? - What are implications of these results in everyday practice?
Advertisement
Related to this article
End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.
Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.
A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
5